Skip to content

Exploration Test for Evaluating the Effectiveness and Safety of Novosis' Osteoarthritis in Post-Spine

A single group, single organ, prospective, and therapeutic search test led by researchers to evaluate the efficacy and safety of Novosis in post-spinal exoskeleton fusion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007522
Enrollment
30
Registered
2022-07-19
Start date
2022-07-25
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Yonsei University Health System, Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients over 19 years of age or with confirmed skeletal maturity (with radiologic evidence of epiphysal closure) 2) Patients requiring bone grafting due to spinal disease* *Here, spinal disease refers to a person who needs extensive posterior arthroplasty or posterior joint removal due to severe intervertebral disk escape or spinal stenosis, or a person with anterior spinal cord or spinal detachment, but is not limited to the disease. 3) Written consent to participation in this clinical study

Exclusion criteria

Exclusion criteria: 1) A person who does not agree to maintain contraception for one year after the procedure if he/she is pregnant, lactating, or a woman of childbearing age 2) Patients with malignancy or active malignancy 3) Patients with a history of cancer in the past and potential for metastasis (Nobosis is applicable if the disease has been cured and has not recurred in the past 5 years) 4) Patients with active infection at the surgical site 5) Patients with uncontrolled diabetes or hypertension or have blood clotting abnormalities 6) Hydroxyapatite, a person who has a history of overreaction to BMP-2 7) a patient with difficulty in follow-up 8) Patients with compartment syndrome of infected limb (limb) 9) For applications requiring strength

Design outcomes

Primary

MeasureTime frame
Bone fusion rate (%) evaluated based on 3D computed tomography (3DCT) results for 12 months after medical device treatment

Secondary

MeasureTime frame
Bone fusion rate (%) evaluated based on simple radiography (X-ray) results for 6 and 12 months after medical treatment

Countries

Korea, Republic of

Contacts

Public Contactpark siyoung

Korea University Anam Hospital

drspine90@gmail.com+82-2-2228-0430

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026